• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING Back to Search Results
Model Number 24653
Device Problems Premature Activation (1484); Failure to Advance (2524)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 11/29/2019
Event Type  malfunction  
Manufacturer Narrative
(b)(6).
 
Event Description
It was reported that the stent partially deployed.The target lesion was located in the superficial femoral artery (sfa) origin.A 6x40x130 eluvia self expanding stent was selected for an endoscopic third ventriculostomy (evt) procedure.An amplatz 35 guidewire was attempted to advance to the lesion area in the sfa by brachial approach.The eluvia delivery system encountered resistance when advancing.It was noted that the eluvia expanded approximately one third around the external iliac artery (eia) and deployment continued at the eia.There were no patient complications reported.
 
Event Description
It was reported that the stent prematurely deployed.The target lesion was located in the superficial femoral artery (sfa) origin.A 6x40x130 eluvia self expanding stent was selected for an endoscopic third ventriculostomy (evt) procedure.An amplatz 35 guidewire was attempted to advance to the lesion area in the sfa by brachial approach.The eluvia delivery system encountered resistance when advancing.It was noted that the eluvia expanded approximately one third around the external iliac artery (eia) and deployment continued at the eia.There were no patient complications reported.It was corrected to "it was reported that the stent prematurely deployed" from "it was reported that the stent partially deployed.".
 
Manufacturer Narrative
(b)(6).Event sentence "it was reported that the stent partially deployed" was corrected to "it was reported that the stent prematurely deployed".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM
Type of Device
STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
MDR Report Key9488438
MDR Text Key173334640
Report Number2134265-2019-15899
Device Sequence Number1
Product Code NIU
Combination Product (y/n)N
PMA/PMN Number
P180011
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup
Report Date 12/18/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/18/2019
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date03/13/2021
Device Model Number24653
Device Catalogue Number24653
Device Lot Number0023568730
Was Device Available for Evaluation? No
Date Manufacturer Received12/02/2019
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-